The Shrinking Discovery Deal Market
Executive Summary
Since 1998, the number of deals between European biotechs and pharmas of all geographies has been shrinking steadily. These numbers shrank even as investors poured money into increasing numbers of biotechs, almost all of them based on a partnering model which was rapidly losing its logical basis.
You may also be interested in...
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
A Learning Lab For Outcomes-Based Risk-Sharing Agreements
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.